 CAMBRIDGE, Mass.--BUSINESS WIRE--Epizyme, Inc. Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that clinical data will be presented at the upcoming 2021 European Society of Medical Oncology ESMO Virtual Congress, taking place on September 16-21, 2021. At the conference there will be two posters on two of the trials examining tazemetostat use in solid tumors. One details updated data from the 